 | • レポートコード：MRC2-11QY04982 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は更年期における血管運動性症状治療のグローバル市場について調査・分析したレポートです。種類別（エステトロール、フェゾリンタント、FP-101、HBN-2、その他）市場規模、用途別（病院、在宅医療、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別更年期における血管運動性症状治療の競争状況、市場シェア ・世界の更年期における血管運動性症状治療市場：種類別市場規模 2015年-2020年（エステトロール、フェゾリンタント、FP-101、HBN-2、その他） ・世界の更年期における血管運動性症状治療市場：種類別市場規模予測 2021年-2026年（エステトロール、フェゾリンタント、FP-101、HBN-2、その他） ・世界の更年期における血管運動性症状治療市場：用途別市場規模 2015年-2020年（病院、在宅医療、クリニック） ・世界の更年期における血管運動性症状治療市場：用途別市場規模予測 2021年-2026年（病院、在宅医療、クリニック） ・北米の更年期における血管運動性症状治療市場分析：米国、カナダ ・ヨーロッパの更年期における血管運動性症状治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの更年期における血管運動性症状治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の更年期における血管運動性症状治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの更年期における血管運動性症状治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Amgen Inc.、EndoCeutics, Inc.、Euroscreen S.A.、MenoGeniX, Inc.、Mithra Pharmaceuticals S.A.、Pherin Pharmaceuticals, Inc.、Pivot Pharmaceuticals Inc、Radius Health, Inc.、TherapeuticsMD, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Vasomotor Symptoms of Menopause Treatment Market
The global Vasomotor Symptoms of Menopause Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Vasomotor Symptoms of Menopause Treatment Scope and Market Size
Vasomotor Symptoms of Menopause Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Vasomotor Symptoms of Menopause Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Amgen Inc.
EndoCeutics, Inc.
Euroscreen S.A.
MenoGeniX, Inc.
Mithra Pharmaceuticals S.A.
Pherin Pharmaceuticals, Inc.
Pivot Pharmaceuticals Inc
Radius Health, Inc.
TherapeuticsMD, Inc.
Market segment by Type, the product can be split into
Estetrol
Fezolinetant
FP-101
HBN-2
Others
Market segment by Application, split into
Hospital
Homecare
Clinic
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Vasomotor Symptoms of Menopause Treatment Revenue
1.4 Market by Type
1.4.1 Global Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Estetrol
1.4.3 Fezolinetant
1.4.4 FP-101
1.4.5 HBN-2
1.4.6 Others
1.5 Market by Application
1.5.1 Global Vasomotor Symptoms of Menopause Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Homecare
1.5.4 Clinic
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Vasomotor Symptoms of Menopause Treatment Market Perspective (2015-2026)
2.2 Global Vasomotor Symptoms of Menopause Treatment Growth Trends by Regions
2.2.1 Vasomotor Symptoms of Menopause Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Vasomotor Symptoms of Menopause Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Vasomotor Symptoms of Menopause Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Vasomotor Symptoms of Menopause Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Vasomotor Symptoms of Menopause Treatment Players by Market Size
3.1.1 Global Top Vasomotor Symptoms of Menopause Treatment Players by Revenue (2015-2020)
3.1.2 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Vasomotor Symptoms of Menopause Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Vasomotor Symptoms of Menopause Treatment Market Concentration Ratio
3.2.1 Global Vasomotor Symptoms of Menopause Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Vasomotor Symptoms of Menopause Treatment Revenue in 2019
3.3 Vasomotor Symptoms of Menopause Treatment Key Players Head office and Area Served
3.4 Key Players Vasomotor Symptoms of Menopause Treatment Product Solution and Service
3.5 Date of Enter into Vasomotor Symptoms of Menopause Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Vasomotor Symptoms of Menopause Treatment Historic Market Size by Type (2015-2020)
4.2 Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020)
5.2 Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Vasomotor Symptoms of Menopause Treatment Market Size (2015-2020)
6.2 Vasomotor Symptoms of Menopause Treatment Key Players in North America (2019-2020)
6.3 North America Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020)
6.4 North America Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Vasomotor Symptoms of Menopause Treatment Market Size (2015-2020)
7.2 Vasomotor Symptoms of Menopause Treatment Key Players in Europe (2019-2020)
7.3 Europe Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020)
7.4 Europe Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020)
8 China
8.1 China Vasomotor Symptoms of Menopause Treatment Market Size (2015-2020)
8.2 Vasomotor Symptoms of Menopause Treatment Key Players in China (2019-2020)
8.3 China Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020)
8.4 China Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Vasomotor Symptoms of Menopause Treatment Market Size (2015-2020)
9.2 Vasomotor Symptoms of Menopause Treatment Key Players in Japan (2019-2020)
9.3 Japan Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020)
9.4 Japan Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Size (2015-2020)
10.2 Vasomotor Symptoms of Menopause Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020)
11 India
11.1 India Vasomotor Symptoms of Menopause Treatment Market Size (2015-2020)
11.2 Vasomotor Symptoms of Menopause Treatment Key Players in India (2019-2020)
11.3 India Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020)
11.4 India Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Vasomotor Symptoms of Menopause Treatment Market Size (2015-2020)
12.2 Vasomotor Symptoms of Menopause Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020)
12.4 Central & South America Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Amgen Inc.
13.1.1 Amgen Inc. Company Details
13.1.2 Amgen Inc. Business Overview
13.1.3 Amgen Inc. Vasomotor Symptoms of Menopause Treatment Introduction
13.1.4 Amgen Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020))
13.1.5 Amgen Inc. Recent Development
13.2 EndoCeutics, Inc.
13.2.1 EndoCeutics, Inc. Company Details
13.2.2 EndoCeutics, Inc. Business Overview
13.2.3 EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
13.2.4 EndoCeutics, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020)
13.2.5 EndoCeutics, Inc. Recent Development
13.3 Euroscreen S.A.
13.3.1 Euroscreen S.A. Company Details
13.3.2 Euroscreen S.A. Business Overview
13.3.3 Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Introduction
13.3.4 Euroscreen S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020)
13.3.5 Euroscreen S.A. Recent Development
13.4 MenoGeniX, Inc.
13.4.1 MenoGeniX, Inc. Company Details
13.4.2 MenoGeniX, Inc. Business Overview
13.4.3 MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
13.4.4 MenoGeniX, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020)
13.4.5 MenoGeniX, Inc. Recent Development
13.5 Mithra Pharmaceuticals S.A.
13.5.1 Mithra Pharmaceuticals S.A. Company Details
13.5.2 Mithra Pharmaceuticals S.A. Business Overview
13.5.3 Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Introduction
13.5.4 Mithra Pharmaceuticals S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020)
13.5.5 Mithra Pharmaceuticals S.A. Recent Development
13.6 Pherin Pharmaceuticals, Inc.
13.6.1 Pherin Pharmaceuticals, Inc. Company Details
13.6.2 Pherin Pharmaceuticals, Inc. Business Overview
13.6.3 Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
13.6.4 Pherin Pharmaceuticals, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020)
13.6.5 Pherin Pharmaceuticals, Inc. Recent Development
13.7 Pivot Pharmaceuticals Inc
13.7.1 Pivot Pharmaceuticals Inc Company Details
13.7.2 Pivot Pharmaceuticals Inc Business Overview
13.7.3 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Introduction
13.7.4 Pivot Pharmaceuticals Inc Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020)
13.7.5 Pivot Pharmaceuticals Inc Recent Development
13.8 Radius Health, Inc.
13.8.1 Radius Health, Inc. Company Details
13.8.2 Radius Health, Inc. Business Overview
13.8.3 Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
13.8.4 Radius Health, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020)
13.8.5 Radius Health, Inc. Recent Development
13.9 TherapeuticsMD, Inc.
13.9.1 TherapeuticsMD, Inc. Company Details
13.9.2 TherapeuticsMD, Inc. Business Overview
13.9.3 TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
13.9.4 TherapeuticsMD, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020)
13.9.5 TherapeuticsMD, Inc. Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Vasomotor Symptoms of Menopause Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Vasomotor Symptoms of Menopause Treatment Revenue
Table 3. Ranking of Global Top Vasomotor Symptoms of Menopause Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Estetrol
Table 6. Key Players of Fezolinetant
Table 7. Key Players of FP-101
Table 8. Key Players of HBN-2
Table 9. Key Players of Others
Table 10. Global Vasomotor Symptoms of Menopause Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Vasomotor Symptoms of Menopause Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Vasomotor Symptoms of Menopause Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Vasomotor Symptoms of Menopause Treatment Market Share by Regions (2015-2020)
Table 14. Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Vasomotor Symptoms of Menopause Treatment Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Vasomotor Symptoms of Menopause Treatment Market Growth Strategy
Table 20. Main Points Interviewed from Key Vasomotor Symptoms of Menopause Treatment Players
Table 21. Global Vasomotor Symptoms of Menopause Treatment Revenue by Players (2015-2020) (Million US$)
Table 22. Global Vasomotor Symptoms of Menopause Treatment Market Share by Players (2015-2020)
Table 23. Global Top Vasomotor Symptoms of Menopause Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vasomotor Symptoms of Menopause Treatment as of 2019)
Table 24. Global Vasomotor Symptoms of Menopause Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Vasomotor Symptoms of Menopause Treatment Product Solution and Service
Table 27. Date of Enter into Vasomotor Symptoms of Menopause Treatment Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020) (Million US$)
Table 30. Global Vasomotor Symptoms of Menopause Treatment Market Size Share by Type (2015-2020)
Table 31. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Type (2021-2026)
Table 32. Global Vasomotor Symptoms of Menopause Treatment Market Size Share by Application (2015-2020)
Table 33. Global Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020) (Million US$)
Table 34. Global Vasomotor Symptoms of Menopause Treatment Market Size Share by Application (2021-2026)
Table 35. North America Key Players Vasomotor Symptoms of Menopause Treatment Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Vasomotor Symptoms of Menopause Treatment Market Share (2019-2020)
Table 37. North America Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020) (Million US$)
Table 38. North America Vasomotor Symptoms of Menopause Treatment Market Share by Type (2015-2020)
Table 39. North America Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. North America Vasomotor Symptoms of Menopause Treatment Market Share by Application (2015-2020)
Table 41. Europe Key Players Vasomotor Symptoms of Menopause Treatment Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Vasomotor Symptoms of Menopause Treatment Market Share (2019-2020)
Table 43. Europe Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Vasomotor Symptoms of Menopause Treatment Market Share by Type (2015-2020)
Table 45. Europe Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Vasomotor Symptoms of Menopause Treatment Market Share by Application (2015-2020)
Table 47. China Key Players Vasomotor Symptoms of Menopause Treatment Revenue (2019-2020) (Million US$)
Table 48. China Key Players Vasomotor Symptoms of Menopause Treatment Market Share (2019-2020)
Table 49. China Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. China Vasomotor Symptoms of Menopause Treatment Market Share by Type (2015-2020)
Table 51. China Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. China Vasomotor Symptoms of Menopause Treatment Market Share by Application (2015-2020)
Table 53. Japan Key Players Vasomotor Symptoms of Menopause Treatment Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Vasomotor Symptoms of Menopause Treatment Market Share (2019-2020)
Table 55. Japan Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Vasomotor Symptoms of Menopause Treatment Market Share by Type (2015-2020)
Table 57. Japan Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Vasomotor Symptoms of Menopause Treatment Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Vasomotor Symptoms of Menopause Treatment Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Vasomotor Symptoms of Menopause Treatment Market Share (2019-2020)
Table 61. Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Share by Type (2015-2020)
Table 63. Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Share by Application (2015-2020)
Table 65. India Key Players Vasomotor Symptoms of Menopause Treatment Revenue (2019-2020) (Million US$)
Table 66. India Key Players Vasomotor Symptoms of Menopause Treatment Market Share (2019-2020)
Table 67. India Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. India Vasomotor Symptoms of Menopause Treatment Market Share by Type (2015-2020)
Table 69. India Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. India Vasomotor Symptoms of Menopause Treatment Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Vasomotor Symptoms of Menopause Treatment Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Vasomotor Symptoms of Menopause Treatment Market Share (2019-2020)
Table 73. Central & South America Vasomotor Symptoms of Menopause Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Vasomotor Symptoms of Menopause Treatment Market Share by Type (2015-2020)
Table 75. Central & South America Vasomotor Symptoms of Menopause Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Vasomotor Symptoms of Menopause Treatment Market Share by Application (2015-2020)
Table 77. Amgen Inc. Company Details
Table 78. Amgen Inc. Business Overview
Table 79. Amgen Inc. Product
Table 80. Amgen Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 81. Amgen Inc. Recent Development
Table 82. EndoCeutics, Inc. Company Details
Table 83. EndoCeutics, Inc. Business Overview
Table 84. EndoCeutics, Inc. Product
Table 85. EndoCeutics, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 86. EndoCeutics, Inc. Recent Development
Table 87. Euroscreen S.A. Company Details
Table 88. Euroscreen S.A. Business Overview
Table 89. Euroscreen S.A. Product
Table 90. Euroscreen S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 91. Euroscreen S.A. Recent Development
Table 92. MenoGeniX, Inc. Company Details
Table 93. MenoGeniX, Inc. Business Overview
Table 94. MenoGeniX, Inc. Product
Table 95. MenoGeniX, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 96. MenoGeniX, Inc. Recent Development
Table 97. Mithra Pharmaceuticals S.A. Company Details
Table 98. Mithra Pharmaceuticals S.A. Business Overview
Table 99. Mithra Pharmaceuticals S.A. Product
Table 100. Mithra Pharmaceuticals S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 101. Mithra Pharmaceuticals S.A. Recent Development
Table 102. Pherin Pharmaceuticals, Inc. Company Details
Table 103. Pherin Pharmaceuticals, Inc. Business Overview
Table 104. Pherin Pharmaceuticals, Inc. Product
Table 105. Pherin Pharmaceuticals, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 106. Pherin Pharmaceuticals, Inc. Recent Development
Table 107. Pivot Pharmaceuticals Inc Company Details
Table 108. Pivot Pharmaceuticals Inc Business Overview
Table 109. Pivot Pharmaceuticals Inc Product
Table 110. Pivot Pharmaceuticals Inc Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 111. Pivot Pharmaceuticals Inc Recent Development
Table 112. Radius Health, Inc. Business Overview
Table 113. Radius Health, Inc. Product
Table 114. Radius Health, Inc. Company Details
Table 115. Radius Health, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 116. Radius Health, Inc. Recent Development
Table 117. TherapeuticsMD, Inc. Company Details
Table 118. TherapeuticsMD, Inc. Business Overview
Table 119. TherapeuticsMD, Inc. Product
Table 120. TherapeuticsMD, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2015-2020) (Million US$)
Table 121. TherapeuticsMD, Inc. Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Vasomotor Symptoms of Menopause Treatment Market Share by Type: 2020 VS 2026
Figure 2. Estetrol Features
Figure 3. Fezolinetant Features
Figure 4. FP-101 Features
Figure 5. HBN-2 Features
Figure 6. Others Features
Figure 7. Global Vasomotor Symptoms of Menopause Treatment Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Homecare Case Studies
Figure 10. Clinic Case Studies
Figure 11. Vasomotor Symptoms of Menopause Treatment Report Years Considered
Figure 12. Global Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Vasomotor Symptoms of Menopause Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Vasomotor Symptoms of Menopause Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Vasomotor Symptoms of Menopause Treatment Market Share by Players in 2019
Figure 17. Global Top Vasomotor Symptoms of Menopause Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vasomotor Symptoms of Menopause Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Vasomotor Symptoms of Menopause Treatment Revenue in 2019
Figure 19. North America Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
更年期障害の世界市場（～2026年） Menopause, also known as the climacteric, is the time in most women's lives when menstrual periods stop permanently, and they are no longer able to bear children. Menopause typically occurs between 49 and 52 years of age. Medical professionals often define menopause as having occurred when a woman h…- 気管支拡張症治療の世界市場（～2026年） Bronchiectasis refers to a condition characterized by damaged airways (tubes) and affect their ability to clear out the mucus. This deposition of mucus leads to bacterial infections and hence resulting in serious and repeated lung infections. Bronchiectasis is a long term condition resulting in seri…
- 統合失調感情障害治療の世界市場（～2026年） Types of schizoaffective disorders include manic, depressive, mixed, and schizoaffective disorders. The regional market for schizoaffective affective disorders is very common in North America, Europe and Asia Pacific. Market Analysis and Insights: Global Schizoaffective Disorders Treatment Market Th…
- 巨細胞性動脈炎治療の世界市場（～2026年） Giant cell arteritis is also known as temporal arteritis, is a type of disease which causes inflammation of medium and large vessels that occurs only in individuals older than 50 years of age. Seasonal variations in the incidence of giant cell arteritis treatment suggest a possible infective origin …
- 軟骨無形成症治療の世界市場（～2026年） Market Analysis and Insights: Global Achondroplasia Treatment Market The global Achondroplasia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Achondroplasia Treatment Scope and Market Size Achondroplasia Tre…